-
Curasight to establish its exclusive uTRACE® animal imaging innovation to obtain regulative approval in EU and U.S.A., with Curium accountable for making and commercialization
-
Curasight eligible for as much as USD 70 mn in advancement and industrial turning points along with double-digit royalties on sales on ultimate commercialization
-
The arrangement supports Curasight’s technique to utilize collaborations as it advances its uPAR theranostic service to detect and treat specific kinds of cancer
COPENHAGEN, Denmark, May 2, 2023 /PRNewswire/ — Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) revealed today that it has actually participated in a special international license and partnership arrangement with Curium Inc. – a worldwide leader in radiopharmaceuticals – for the advancement and commercialization of uTRACE® for usage in prostate cancer.
Under the regards to the arrangement, Curasight will establish its exclusive uTRACE® innovation for usage in prostate cancer up until regulative approval is approved in the EU and U.S.A.. Curium will have obligation for the industrial manufacture of uTRACE® and global commercialization. Curasight is qualified to receive as much as USD 70 mn in advancement and industrial turning points along with double-digit portion royalties on sales in significant markets upon ultimate commercialization.
Curasight intends to place uTRACE® as a first-in-class animal tracer that can work as an alternative or supplement to conventional biopsies for the examination of clients with prostate cancer in active monitoring. Curasight just recently received feedback from the United States Food and Drug Administration (FDA) in a pre-IND conference about the advancement prepare for the 64Cu-identified variation of uTRACE® for usage in prostate cancer.
“We are enjoyed sign this collaboration with Curium, which our company believe supplies even more recognition of our uTRACE® platform and its usage in prostate cancer. Our partnership sets Curasight’s strengths in the advancement of uTRACE® and Curium’s tested know-how, capability, and international performance history in the production and commercialization of radiopharmaceuticals,” said Curasight’s CEO Ulrich Krasilnikoff. “This collaboration supports additional advancement of our diagnostic platform, bringing us closer to satisfying our aspiration of assisting a a great deal of prostate cancer clients.”
“As the international leader in nuclear medication, Curium is devoted to establishing life-saving diagnostic and treatment services for cancer clients. We are delighted about the chance to additional broaden our ingenious Copper-64 identified animal diagnostic franchise in an appealing sign. Our collaboration with Curasight will utilize Curium’s international footprint, Copper 64 know-how and know-how in prostate cancer to bring this ingenious service to clients and health care specialists around the globe,” included Chaitanya Tatineni, Curium Chief M&A Officer and Head of Curium’s licensing and collaboration programs.
The uTRACE® platform becomes part of Curasights uPAR theranostic service, comprised of its uTRACE® diagnostic innovation and its uTREAT® targeted treatment innovation. By picturing the cancer in a boosted and smart method, the uTRACE® platform intends to supply a more precise medical diagnosis in specific kinds of cancer consisting of prostate cancer, which can support a customized treatment service for each client. The innovation has actually been checked in numerous Phase 2 medical trials. Curasight will keep all rights to establish and advertise uTRACE® in indicators outside prostate cancer.
For more info about Curasight:
Ulrich Krasilnikoff, CEO
Phone: +45 22 83 01 60
Email: [email protected]
www.curasight.com
For more info about Curium:
Ross Bethell, VP Head of Global Communications, Curium
Email: [email protected]
www.curiumpharma.com
The following files are available for download:
